<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier		NA
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: page no/section/legend)	n/a
Cell lines: Provide species information, strain.		NA
Provide accession number in repository OR		
supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of		NA
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: page no/section/legend)	n/a
Laboratory animals: Provide species, strain, sex, age,	i co (indicate vinere provideur page no/section/legend)	NA
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		NA
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		NA
in repository (where relevant) OR RRID		
Plants and microbes	Yes (indicate where provided: page no/section/legend)	n/a
Plants: provide species and strain, unique accession		NA
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		NA
accession number if available, and source		
Human research participants	Yes (indicate where provided: page no/section/legend)	n/a
Identify authority granting ethics approval (IRB or		NA
equivalent committee(s), provide reference number		1
for approval.		
Provide statement confirming informed consent		NA
obtained from study participants.		
Report on age and sex for all study participants.		NA

<u>Design</u>

Study protocol	Yes (indicate where provided: page no/section/legend)	n/a
For clinical trials, provide the trial registration		Ν
number OR cite DOI in manuscript.		Α
Laboratory protocol	Yes (indicate where provided: page no/section/legend)	n/a
Provide DOI or other citation details if detailed step-		, N
by-step protocols are available.		А
Experimental study design (statistics details)	Yes (indicate where provided: page no/section/legend)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		N
Randomisation		Ν
Blinding		N
Inclusion/exclusion criteria		Ν
Sample definition and in-laboratory replication	Yes (indicate where provided: page no/section/legend)	n/a
State number of times the experiment was		Ν
replicated in laboratory		Α
Define whether data describe technical or biological		N
replicates		Α
Ethics	Yes (indicate where provided: page no/section/legend)	n/a
Studies involving human participants: State details of		Ν
authority granting ethics approval (IRB or equivalent		Α
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details		N
of authority granting ethics approval (IRB or		А
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		Ν
relevant permits obtained, provide details of		Α
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: page no/section/legend)	n/a
		N
If study is subject to dual use research of concern,		IN
If study is subject to dual use research of concern, state the authority granting approval and reference		A

<u>Analysis</u>

Attrition	Yes (indicate where provided: page no/section/legend)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		N A
Statistics	Yes (indicate where provided: page no/section/legend)	n/a
Describe statistical tests used and justify choice of tests.	Statistical methods in detail described in the paper	
Data Availability	Yes (indicate where provided: page no/section/legend)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		N A
If data are publicly available, provide accession number in repository or DOI or URL.		N A
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	We accurately referred all instances when publicly available data was used.	
Code Availability	Yes (indicate where provided: page no/section/legend)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	YES	
If code is publicly available, provide accession number in repository, or DOI or URL.	There are no big dataset associated with the paper, all the code and necessary data available are available <u>http://doi.org/10.5281/zenodo.4494404</u> Vrnmf R package is available at http://doi.org/10.5281/zenodo.4494404	

Reporting

Adherence to community standards	Yes (indicate where provided: page no/section/legend)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.		N A